This special series on “Advances in Treatment for Melanoma” is edited by Dr. María González Cao.
María González Cao, MD, PhD
Translational Cancer Research Unit, Dr. Rosell Oncology Institute (IOR), Dexeus University Hospital, Barcelona, Spain
Dr. María González Cao is the Chair of the Melanoma Medical Oncology at the Institut Oncològic Dr. Rosell, University Hospital Dexeus in Barcelona. She works in immunotherapy research, particularly for challenging cancers with limited treatment options and special populations, including patients with HIV. She is actively involved in investigator-initiated clinical trials and leads several translational research projects, focusing on immuno-oncology and targeted therapies in melanoma and lung cancer.
Dr. González Cao serves as the Scientific Secretary of the Spanish Melanoma Group from 2010 and is the principal investigator in numerous Phase I, II, and III clinical trials. She has authored over 100 peer-reviewed publications and presented at numerous international conferences.
Series outline:
- Editorial on advances in treatment for melanoma
- Fragmentomics analysis in melanoma
- Intratumoral therapy for melanoma
- Neoadjuvant therapy in melanoma
- Cell based therapy in melanoma
- Treatment beyond first line anti PD-1 based therapy: ADCs and soluble TCRs
- Predicting relapse of low-risk melanomas
- TBK1-mediated melanoma progression and brain metastasis
- Novel targeted drugs in melanoma
- Chrono-immunotherapy in melanoma
- Predictive factors of response to TIL therapy in melanoma
Disclosure:
The series “Advances in Treatment for Melanoma” was commissioned by the editorial office, Annals of Translational Medicine without any sponsorship or funding. María González Cao is serving as the unpaid Guest Editor for the series.